Coremend (TB4 · KPV · BPC-157) (Blend)

Thymosin beta-4 is a 43-amino-acid acidic peptide first isolated from thymic tissue and subsequently identified as one of the most abundant intracellular actin-sequestering peptides in mammalian cell types. It functions as a 1:1 G-actin-binding research peptide and contributes to the maintenance of a pool of monomeric actin available for rapid cytoskeletal reorganization in cellular research models.

TB-500 is supplied as a synthetic full-length analog of the thymosin beta-4 sequence, allowing laboratory research studies to use a defined reference compound for actin-binding research and cytoskeletal dynamics research. The sequence retains the central LKKTET actin-binding motif (residues 17-22), which has been mapped through mutational and structural research as the principal contact region with G-actin in research models.

This positioning at the intersection of cytoskeletal dynamics research, cellular-process research, and structure-activity research has made TB-500 an experimental research compound of considerable interest in laboratory research studies of actin-binding pharmacology, endothelial cellular-process research, and comparative thymosin beta-4 fragment research.

Melanocortin peptides have long been studied for their role in pigmentation, inflammatory signaling, and immune regulation. Alpha-melanocyte-stimulating hormone (α-MSH) is the most extensively investigated member of this family and is known for potent inflammatory-pathway modulation. During the late 1990s, structure-activity research identified the C-terminal tripeptide of α-MSH, Lys-Pro-Val, as a minimal sequence that retains much of the anti-inflammatory profile of the parent hormone.

Subsequent research demonstrated that KPV exerts its activity through a melanocortin-receptor-independent mechanism. Cellular uptake studies suggested that KPV can enter epithelial and immune cells, where it appears to interfere with intracellular inflammatory signaling rather than binding extracellular receptors. This distinct mode of action has positioned KPV as a research compound of interest for investigators exploring targeted, receptor-independent inflammatory-pathway regulation.

Today, KPV is a standard research tool for studying mucosal inflammation, epithelial barrier biology, and the broader concept of small-peptide-mediated transcriptional control. Its compact size, oral and topical research-format compatibility, and clearly defined structure make it a frequent reference compound in laboratory work on inflammatory bowel research, skin biology, and immune-cell signaling.

BPC-157 is classified as a synthetic gastric-pentadecapeptide research compound. The sequence was originally derived from a larger protein identified in gastric extracts, and the 15-residue synthetic version has become a widely used reference compound in cellular-pathway research and nitric oxide signalling research.

Laboratory research studies have characterized BPC-157 as a stable research peptide in acidic conditions, a property that distinguishes it from many other bioactive research peptides. This stability profile has made it a useful tool in laboratory research studies of gastric-tissue research, where peptide integrity under acidic conditions is an important methodological consideration.

Mechanistic research has investigated BPC-157 engagement with vascular endothelial pathways, including VEGFR2 signalling research and the Akt-eNOS axis. Additional research models have examined interaction with the broader nitric oxide system, Src-Cav-1-eNOS signalling, and inflammatory-pathway research. This positioning at the intersection of nitric oxide signalling research, endothelial cellular-process research, and gastric-tissue research has made BPC-157 a research peptide of considerable interest in laboratory research studies of pentadecapeptide pharmacology and integrated cellular-pathway signalling.

TB-500 Structure

1. Actin-Binding and Cytoskeletal Dynamics Research

TB-500 engages monomeric G-actin in a 1:1 stoichiometry through its central LKKTET actin-binding motif. In laboratory research studies, this interaction sequesters G-actin and modulates the equilibrium between monomeric and filamentous actin populations, supporting investigations into cytoskeletal dynamics research and cellular-process research models.

2. Cellular-Process Signalling Research

TB-500 has been investigated in cellular research models for its interaction with endothelial and epithelial cell migration pathways. Research models indicate that the full-length thymosin beta-4 sequence engages cellular-process signalling research relevant to cellular-pathway research and structure-activity research with discrete actin-binding fragments such as LKKTETQ.

3. Inflammatory-Pathway Research

Laboratory research studies have examined how TB-500 modulates inflammatory-pathway research markers in cellular and animal research models. These investigations are relevant to cytokine-signalling research and comparative research on thymosin beta-4 active-site fragments.

4. Structure-Activity Research

By supplying the full-length 43-residue sequence, TB-500 enables comparative research alongside discrete fragments such as the heptapeptide LKKTETQ (residues 17-23). This supports structure-activity research investigating how isolated actin-binding domains compare to the parent peptide in actin-binding research and cellular-process research models.

Research Applications

Conclusion

TB-500 is a synthetic full-length thymosin beta-4 research peptide that engages monomeric G-actin through its central LKKTET motif and supports laboratory research studies of cytoskeletal dynamics research, cellular-process research, and inflammatory-pathway research. Its defined sequence and 1:1 actin-binding profile make it a valuable reference compound for laboratory research studies of actin-binding pharmacology and comparative research with thymosin beta-4 active-site fragments.

1. NF-κB Pathway Modulation

KPV is studied as an intracellular modulator of the NF-κB inflammatory signaling cascade. Research models suggest that the tripeptide can enter cells via peptide-transporter systems such as PEPT1, accumulate in the cytoplasm, and reduce nuclear translocation of NF-κB. This in turn lowers transcription of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 in epithelial and immune-cell models.

2. Receptor-Independent Anti-Inflammatory Activity

Unlike the parent α-MSH peptide, KPV is reported to act through a melanocortin-receptor-independent mechanism. Investigations indicate that its inflammatory-pathway effects persist in research systems lacking classical melanocortin receptors, supporting a model in which KPV interacts with intracellular targets rather than cell-surface receptors.

3. Epithelial Barrier and Mucosal Research

KPV is examined for its influence on intestinal epithelial integrity in research models of mucosal inflammation. Studies suggest reduced permeability markers, preserved tight-junction protein expression, and lower neutrophil infiltration in colitis-type research designs, supporting its use as a tool compound in gut-barrier biology.

4. Mast Cell and Immune-Cell Signaling

Experimental research has investigated KPV in relation to mast-cell degranulation, eosinophil recruitment, and macrophage cytokine output. These findings support broader interest in the peptide as a research compound for studying allergic-type, skin-inflammatory, and oral-mucosal research models.

Research Applications

Conclusion

KPV is a melanocortin-derived tripeptide investigated as a receptor-independent modulator of intracellular inflammatory signaling. By reducing NF-κB-driven cytokine expression and supporting epithelial barrier integrity in research models, it serves as a valuable research compound in laboratory studies of mucosal inflammation, gut biology, and small-peptide anti-inflammatory mechanisms.

1. VEGFR2 Signalling Research

BPC-157 has been investigated in laboratory research studies for engagement with vascular endothelial growth factor receptor-2 (VEGFR2) signalling. Mechanistic research models indicate that BPC-157 modulates VEGFR2 expression and internalization, supporting investigations into endothelial cellular-process research and vascular-pathway research (Hsieh et al., 2017, Journal of Molecular Medicine).

2. Akt-eNOS Axis and Nitric Oxide Signalling Research

Laboratory research studies have characterized BPC-157 engagement with the Akt-endothelial nitric oxide synthase (eNOS) axis. This signalling research is associated with nitric oxide production in endothelial research models and has been investigated as a downstream consequence of VEGFR2 modulation in cellular-pathway research.

3. Src-Cav-1-eNOS Pathway Research

Research models have also characterized BPC-157 engagement with the Src-Caveolin-1-eNOS pathway. Mechanistic research indicates that BPC-157 enhances phosphorylation of Src, Cav-1 and eNOS and reduces Cav-1-eNOS binding in vascular research models, supporting investigations into nitric oxide signalling research independent of canonical VEGFR2 input (Hsieh et al., 2020, Scientific Reports).

4. Gastric-Tissue Research Models

Laboratory research studies have investigated BPC-157 stability in acidic conditions and its engagement with gastric-tissue research models. These investigations support research on pentadecapeptide pharmacology and cellular-pathway research relevant to gastric-tissue research.

Research Applications

Conclusion

BPC-157 is a synthetic 15-residue gastric-pentadecapeptide research compound that engages VEGFR2 signalling, the Akt-eNOS axis, and the Src-Cav-1-eNOS pathway in research models. Its combination of acidic-condition stability and characterized engagement with nitric oxide signalling research makes it a valuable investigational laboratory peptide for laboratory research studies in cellular-pathway research, endothelial cellular-process research, and gastric-tissue research models.